From setting the differentiation strategy early in product development through completion of value dossiers, Thomson Reuters can assist in data capture, analysis, modeling, and completion of submission documents to effectively demonstrate evidence of product value to key stakeholders. Our Economic Valuation and Market Access services help you plan, test, confirm, package, and communicate your market differentiation strategy, thereby demonstrating product value with the evidence required for compelling submissions.

Strategic Consulting

From your earliest thinking around commercialization of a new compound to drafting the Target Product Profile and creating the pre-launch differentiation strategy, our experience helps you develop an effective value demonstration plan for approval and launch. With intimate knowledge of your product, we can then help you continue to build compelling evidence of your product's value post-launch.

Patient-Reported Outcomes (PRO)

Selecting the best PRO measure for your clinical trial program requires a thorough understanding of your products' attributes, development programs of your key competitors, and current regulatory and reimbursement environments.  The decision to develop a new PRO instrument versus using an existing instrument can be critical to the long term value proposition of new therapies and medical technologies.  The Thomson Reuters PRO team brings the technical expertise and years of industry experience necessary to guide these decisions.

ECONOMIC MODELING

As part of a multi-disciplinary team working with you on an ongoing research agenda, Thomson Reuters provides strategic consultation to help you identify the best approach for using scientifically-valid health economic models informed by real-world data to generate compelling evidence about the clinical-economic value of your products. We are experts in developing health economic models that payers trust as credible and transparent.  Our extensive model design and building experience covers both simple and complex models, ranging from basic cost calculators to sophisticated Markov health state models. Our models are proven decision-making tools that provide payers and government stakeholders with realistic, practical, and convincing estimates of the value of your product in real-world clinical practice.

Value Dossier Preparation

We have strong experience in compiling and submitting stakeholder-focused briefs and global value dossiers to reimbursement authorities that fully describe the unmet need, the differential benefits of your product, its economic value, and budgetary impact.

BENEFITS

  • Our in-industry experience creating value demonstrations and communicating with the FDA, EMA, and payers and reimbursement authorities yields more competitive evidence documents and greater success in securing approved label language.
  • From strategy through dossier submission, you work with one team who knows your product intimately.  We can continue to work with you as your product evolves through in-market studies.
  • Economic models become more relevant to payers when Thomson Reuters MarketScan® claims data are used to supplement limitations of clinical trial results.

Budget Impact and Cost Effectiveness Models

From elegantly simple to large and complex, Thomson Reuters modelers develop spreadsheet and software-optimized models to provide you with effective, interactive tools for a compelling demonstration of your product's value to payers and for submission in value dossiers.